Avalo Therapeutics, Inc. 8-K

What Happened
Avalo Therapeutics, Inc. (AVTX) filed an 8-K on May 7, 2026 announcing a registered public offering. The company agreed to sell 19,730,000 shares of common stock at $17.75 per share and pre‑funded warrants to purchase up to 1,400,000 shares at $17.749 each. Underwriters Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc. had a 30‑day option to buy up to an additional 3,169,500 shares, which they exercised in full on May 6, 2026. The offering is expected to close on May 7, 2026, subject to customary conditions.

Key Details

• Offering: 19,730,000 common shares at $17.75 and pre‑funded warrants for up to 1,400,000 shares at $17.749.
• Overallotment: Underwriters exercised option for 3,169,500 additional shares on May 6, 2026.
• Estimated net proceeds: Approximately $405.0 million after underwriting discounts, commissions and expenses.
• Cash position (preliminary): ~$82.0 million in cash, cash equivalents and short‑term investments as of March 31, 2026 (unaudited, preliminary).
• Use of proceeds: To advance clinical development of abdakibart (including Phase 3 topline data release), and for working capital and general corporate purposes.
• Pre‑Funded Warrants: Exercisable for one share at $0.001 (cash or cashless exercise); holder ownership limits apply (initially elected at 4.99% or 9.99%, adjustable up to 19.99% with notice).

Why It Matters
This offering materially increases Avalo’s available capital, which the company says, together with existing cash, should fund operations into 2029 and support key clinical milestones for abdakibart. Investors should note the preliminary nature of the March 31 cash figure (unaudited) and that the issuance will dilute existing shareholders depending on the number of shares ultimately issued or exercised. The filing is a financing event—not operational results—and includes customary underwriting agreements and investor protections.